Supply Chain Intelligence

Aytu BioPharma, Inc. Supply Chain

AYTU supply chain intelligence for Aytu BioPharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

AYTU ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
12Customers
3Debt Items
20Related Chains

Aytu BioPharma, Inc. Suppliers

TickerNameConfidenceEvidence
VENDOR VENDOR 90% In fiscal 2025, the Company entered into negotiations with a vendor related to certain variable interest accruals that reduce revenue for the Company's ADHD Portfolio.
TEVJF Teva Pharmaceutical Industries Limited 72% Actavis filed an ANDA with the FDA for a generic version of Adzenys. On October 17, 2017, we entered into a Settlement Agreement and a Licensing Agreement with Actavis (which is now owned by Teva Pha…
TEVJF Teva Pharmaceutical Industries Limited 72% Reciprocal relationship from TEVJF graph: Reciprocal relationship from AYTU graph: Reciprocal relationship from TEVJF graph: Reciprocal relationship from AYTU graph: Reciprocal relationship from TEVJ…
ZVRA Zevra Therapeutics, Inc. 72% Reciprocal relationship from ZVRA graph: Reciprocal relationship from AYTU graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from AYTU graph: Reciprocal relationship from ZVRA g…

Aytu BioPharma, Inc. Customers

TickerNameConfidenceEvidence
THREE-CUSTOMERS THREE-CUSTOMERS 92% Three customers contributed greater than 10% of our gross revenue during the years ended June 30, 2024, and 2023.
ORANY ORANY 72% ification. The Commercialization Agreement can be terminated at any time upon mutual agreement between the Company and Fabre-Kramer. Either party can terminate the Commercialization Agreement at any …
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from AYTU graph: ification. The Commercialization Agreement can be terminated at any time upon mutual agreement between the Company a…
TEVJF Teva Pharmaceutical Industries Limited 72% Reciprocal relationship from TEVJF graph: Reciprocal relationship from AYTU graph: Actavis filed an ANDA with the FDA for a generic version of Adzenys. On October 17, 2017, we entered into a Settleme…
TEVJF Teva Pharmaceutical Industries Limited 72% Actavis filed an ANDA with the FDA for a generic version of Adzenys. On October 17, 2017, we entered into a Settlement Agreement and a Licensing Agreement with Actavis (which is now owned by Teva Pha…
ZVRA Zevra Therapeutics, Inc. 72% Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neuro…
DENOVO-BIOPHARMA-LLC DENOVO-BIOPHARMA-LLC 62% the year ended June 30, 2024, gross profit decreased by 19% compared to the year ended June 30, 2023. Gross margin increased to 67% for the year ended June 30, 2024, compared to 62% for the year ende…
HALO-PHARMACEUTICAL-INC HALO-PHARMACEUTICAL-INC 62% t the pricing, profitability or commercial appeal of pharmaceutical products; and ​ ● our inability to effectively identify and align with commercial partners outside the United States, or the inabil…
INNOVUS-PHARMACEUTICALS-INC INNOVUS-PHARMACEUTICALS-INC 62% s Acquisition, the Company acquired developed product technology for the production and sale of Adzenys and Cotempla. The formulations for the ADHD products are protected by patented technology. The …
MAXIM-GROUP-LLC MAXIM-GROUP-LLC 62% the year ended June 30, 2024, gross profit decreased by 19% compared to the year ended June 30, 2023. Gross margin increased to 67% for the year ended June 30, 2024, compared to 62% for the year ende…
MEDOMIE-PHARMA-LTD MEDOMIE-PHARMA-LTD 62% logy and biopharmaceutical industries, Aytu management and our Board regularly reviews our performance, prospects and risks such as the potential impact to our business resulting from the Company’s c…
TRIS-PHARMA-INC TRIS-PHARMA-INC 62% uired product technology rights $ 41,268 $ ( 13,184 ) $ 28,084 10.5 Acquired technology rights 30,200 ( 5,831 ) 24,369 13.8 Total definite-lived intangible assets $ 71,468 $ ( 19,015 ) $ 52,453 12.0 …

Aytu BioPharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
AYTU-DEBT-8018 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-06-30.
AYTU-DEBT Debt stack $21.8M 90% Market cache reports total debt of $21.8M.
AYTU-DEBT-8017 Warrants outstanding: 149552 90% xbrl warrant detail from xbrl 2024-06-30.

Aytu BioPharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Aytu BioPharma, Inc..

Aytu BioPharma, Inc. Ownership

HolderNameConfidenceEvidence
AYTU-OWNER-NANTAHALA-CAPITAL-MANAGEMENT-LLC Nantahala Capital Management, LLC 90% 13F overlay lists Nantahala Capital Management, LLC as top holder; 38 tracked holders.

Aytu BioPharma, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ORANY ORANGE 100.00 1 ['customer']
TEVA Teva Pharmaceutical Industries Limited 100.00 2
RDY Dr. Reddy's Laboratories Limited 100.00 2
ALVO Alvotech 100.00 2
SNYNF Sanofi 100.00 2
ZVRA Zevra Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
DARE Daré Bioscience, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
AMZE Amaze Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
EQR Equity Residential 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
SCNX Scienture Holdings, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CORT Corcept Therapeutics Incorporated 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
View AYTU supply chain intel →

Explore the full interactive supply chain map for Aytu BioPharma, Inc..

Open AYTU supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map